LLY - Lilly/Incyte's baricitinib shows additional benefit in hospitalized COVID-19 patients

Eli Lilly ([[LLY]] -0.5%) and its collaborating partner Incyte ([[INCY]] +0.1%) have announced additional efficacy and safety data from Adaptive COVID-19 treatment trial (ACTT-2), demonstrating baricitinib in combination with remdesivir reduced recovery time and improved clinical outcomes for patients with COVID-19 infection, compared with remdesivir alone.Most significant benefits were observed in patients requiring supplemental oxygen and those who required high-flow oxygen/non-invasive ventilation.As previously reported, ACTT-2 achieved the primary endpoint, demonstrating that the overall patient population treated with baricitinib+remdesivir combo improved their median time to recovery from 8 to 7 days in comparison to remdesivir, a 12.5% improvement.New data showed numerical decrease in death (35%) through Day 29 was observed in patients treated with baricitinib plus remdesivir compared to remdesivir alone (5.1% vs. 7.8%), respectively.No new safety signals were observed for baricitinib-treated patients in this study.Last week's announced new data showed that the odds of improvement in clinical status at day 15

For further details see:

Lilly/Incyte's baricitinib shows additional benefit in hospitalized COVID-19 patients